Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Forward

 
Since the nineteen seventies, quality of health care has become an important topic for discussion and action in the health care systems all over the world.

In every country today, the capacity of the health care system is challenged. Technological advances offer new drugs, procedures, devices and diagnostic tests that promise improved health. The global concern is how to assure the quality of care while limited resources are used wisely. An especially important challenge in the current condition of Lebanon's health care is to carry out an evaluation of both the health status of the people and the functioning of health care services.

Most countries have nowadays some action going in the ever-expanding field of healthcare quality improvement. One approach that is gaining acceptance around the world is accreditation. Besides its basic purpose of assessing hospitals' compliance with standards, it could play an educative, consultative and informative role, and act as a bridge between the various stakeholders that provides a platform for continued dialogue.

As part of the health reform agenda, the Ministry of Public Health has taken the initiative to address quality management in all its dimensions by driving and supporting the establishment of an accreditation system for hospitals.

To this end, a consultant, Overseas Projects Corporation of Victoria (Australia), was contracted to complete an accreditation manual for acute hospitals in Lebanon. The Health Sector Rehabilitation Project, financed by a loan from the World Bank, supported and supervised this project.
The Manual has been locally developed with the pilot survey hospitals and other major stakeholders, and serves as the first step in the evolution of hospital accreditation in Lebanon. It is expected that all hospitals will be surveyed against the Manual in 2001-2002.

I commend this first edition of the Manual to all acute hospitals, as it signals the way ahead for the accreditation of hospitals, based on quality assurance and quality improvement in patient care.

This language of health care quality measurement and improvement will be continuously refined, improved and updated. Therefore, it is anticipated that the Manual will be reviewed on a regular basis to reflect the further development of Standards.
Accreditation Standards are always a "work in progress". In this spirit, we welcome constructive suggestions on their modification and improvement.

Quality cannot be an accident; it is always the result of high intentions, sincere effort, intelligent direction and skillful execution. It represents the wise choice of many alternatives.

Providers and professionals in health care are the natural partners in quality improvement. Through accreditation, we can combine our efforts, in an innovative partnership, towards the achievement of a better health status for our people.
 
 
Dr. Walid Ammar
 
Director General,
 
Ministry of Public Health,
 
Lebanon
    ...
    113
    ...
ATC Name B/G Ingredients Dosage Form Price
L01EA04 BOSULIF B Bosutinib - 400mg 400mg Tablet, film coated 123,564,667 L.L
L01EA04 BOSULIF B Bosutinib - 500mg 500mg Tablet, film coated 154,453,246 L.L
L01EA04 BOSULIF B Bosutinib - 400mg 400mg Tablet, film coated L.L
L01EA04 BOSULIF B Bosutinib - 500mg 500mg Tablet, film coated L.L
L01EA05 ICLUSIG B Ponatinib - 15mg 15mg Tablet, film coated 103,555,839 L.L
L01EA05 ICLUSIG B Ponatinib - 45mg 45mg Tablet, film coated 207,092,651 L.L
L01EB01 IRESSA B Gefitinib - 250mg 250mg Tablet, fim coated 135,027,509 L.L
L01EB01 APO-GEFITINIB G Gefitinib - 250mg 250mg Tablet 87,345,820 L.L
L01EB01 GEFITINIB ARROW G Gefitinib - 250mg 250mg Tablet, coated 85,330,070 L.L
L01EB01 GEFITINIB BIOGARAN G Gefitinib - 250mg 250mg Tablet, coated 87,070,893 L.L
L01EB01 GEFITINIB BIOGARAN G Gefitinib - 250mg 250mg Tablet, coated L.L
L01EB01 GEFITINIB ARROW G Gefitinib - 250mg 250mg Tablet, coated L.L
L01EB02 APO-ERLOTINIB G Erlotinib (HCl) - 100mg 100mg Tablet 79,672,726 L.L
L01EB02 MIRATA G Erlotinib (HCl) - 100mg 100mg Tablet, film coated 77,379,009 L.L
L01EB02 TARESSA 100 G Erlotinib (HCl) - 100mg 100mg Tablet, film coated 82,247,256 L.L
L01EB02 APO-ERLOTINIB G Erlotinib (HCl) - 150mg 150mg Tablet 91,523,229 L.L
L01EB02 MIRATA G Erlotinib (HCl) - 150mg 150mg Tablet, film coated 88,599,923 L.L
L01EB02 TARESSA 150 G Erlotinib (HCl) - 150mg 150mg Tablet, film coated 98,617,813 L.L
L01EB04 TAGRISSO B Osimertinib - 80mg 80mg Tablet, film coated 603,192,941 L.L
L01EC01 ZELBORAF B Vemurafenib - 240mg 240mg Tablet, film coated 142,041,587 L.L
L01ED01 XALKORI B Crizotinib - 250mg 250mg Capsule 347,644,061 L.L
L01ED01 XALKORI B Crizotinib - 200mg 200mg Capsule 347,644,061 L.L
L01ED01 XALKORI B Crizotinib - 250mg 250mg Capsule L.L
L01ED03 ALECENSA B Alectinib - 150mg 150mg Capsule, hard 490,837,809 L.L
L01ED03 ALECENSA B Alectinib - 150mg 150mg Capsule, hard L.L
L01ED04 ALUNBRIG B Brigatinib - 30mg 30mg Tablet, film coated 124,685,776 L.L
L01ED04 ALUNBRIG B Brigatinib - 90mg 90mg Tablet, film coated 374,059,747 L.L
L01ED04 ALUNBRIG B Brigatinib - 180mg 180mg Tablet, film coated 493,595,998 L.L
L01ED05 LORBRENA B Lorlatinib - 25mg 25mg Tablet 134,559,469 L.L
L01ED05 LORBRENA B Lorlatinib - 100mg 100mg Tablet 403,677,371 L.L
    ...
    113
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025